-
Product Insights
NewTissue Heart Valves Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Tissue Heart Valves Pipeline Market Report Overview Tissue Heart Valves are a combination of tissue and synthetic biomaterials with the tissue itself being flexible. Bovine and porcine valves are included here. The Tissue Heart Valves pipeline market report provides key information and data related to extensive coverage of the Tissue Heart Valves under development. The report provides review details of major pipeline products which include product description, licensing and collaboration details, and other developmental activities including pipeline territories, regulatory paths,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SB-061 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SB-061 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SB-061 in Osteoarthritis Pain Drug Details: SB-061 is under development for the...
-
Product Insights
Fistula – Drugs In Development, 2023
Global Markets Direct’s, ‘Fistula - Drugs In Development, 2023’, provides an overview of the Fistula pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fistula, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Optic Nerve Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Nerve Injury - Drugs In Development, 2023’, provides an overview of the Optic Nerve Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Facioscapulohumeral Muscular Dystrophy (FSHD) - Drugs In Development, 2023’, provides an overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Facioscapulohumeral Muscular Dystrophy (FSHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVDX-3 in Bone Fracture
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVDX-3 in Bone Fracture report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVDX-3 in Bone Fracture Drug Details: NVD-X3 is under development for hard...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVDX-3 in Degenerative Spondylolisthesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVDX-3 in Degenerative Spondylolisthesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVDX-3 in Degenerative Spondylolisthesis Drug Details: NVD-X3 is under development for hard...